Cushing's syndrome differential diagnosis: Difference between revisions
No edit summary |
Ahmed Younes (talk | contribs) No edit summary |
||
(11 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Cushing%27s_syndrome]] | |||
{{CMG}} {{AE}} {{MMF}} | {{CMG}} {{AE}} {{MMF}} | ||
Line 6: | Line 6: | ||
Cushing's syndrome must be differentiated from other diseases that cause [[hypertension]], [[obesity]], and [[hyperandrogenism]], such as [[Metabolic syndrome X]] and pseudo-Cushing's syndrome. | Cushing's syndrome must be differentiated from other diseases that cause [[hypertension]], [[obesity]], and [[hyperandrogenism]], such as [[Metabolic syndrome X]] and pseudo-Cushing's syndrome. | ||
==Differentiating Cushing's | ==Differentiating Cushing's Syndrome From Other Diseases== | ||
=== Differentials based on hypertension, hyperandrogenism and obesity === | |||
The table below summarizes the findings that differentiate Cushing's disease from other conditions that may cause [[Hypertension|hypertensio]]<nowiki/>n, [[hyperandrogenism]], and [[obesity]]. Facial [[plethora]], [[skin changes]], [[osteoporosis]], [[nephrolithiasis]] and [[neuropsychiatric]] conditions should raise the concern for Cushing's syndrome.<ref name="pmid11253984">{{cite journal |vauthors=Boscaro M, Barzon L, Fallo F, Sonino N |title=Cushing's syndrome |journal=Lancet |volume=357 |issue=9258 |pages=783–91 |year=2001 |pmid=11253984 |doi=10.1016/S0140-6736(00)04172-6 |url=}}</ref><ref name="pmid11571938">{{cite journal |vauthors=Findling JW, Raff H |title=Diagnosis and differential diagnosis of Cushing's syndrome |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=3 |pages=729–47 |year=2001 |pmid=11571938 |doi= |url=}}</ref><ref name="pmid9793762">{{cite journal |vauthors=Newell-Price J, Trainer P, Besser M, Grossman A |title=The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states |journal=Endocr. Rev. |volume=19 |issue=5 |pages=647–72 |year=1998 |pmid=9793762 |doi=10.1210/edrv.19.5.0346 |url=}}</ref><ref name="urlHow Is Metabolic Syndrome Diagnosed? - NHLBI, NIH">{{cite web |url=https://www.nhlbi.nih.gov/health/health-topics/topics/ms/diagnosis |title=How Is Metabolic Syndrome Diagnosed? - NHLBI, NIH |format= |work= |accessdate=}}</ref> | The table below summarizes the findings that differentiate Cushing's disease from other conditions that may cause [[Hypertension|hypertensio]]<nowiki/>n, [[hyperandrogenism]], and [[obesity]]. Facial [[plethora]], [[skin changes]], [[osteoporosis]], [[nephrolithiasis]] and [[neuropsychiatric]] conditions should raise the concern for Cushing's syndrome.<ref name="pmid11253984">{{cite journal |vauthors=Boscaro M, Barzon L, Fallo F, Sonino N |title=Cushing's syndrome |journal=Lancet |volume=357 |issue=9258 |pages=783–91 |year=2001 |pmid=11253984 |doi=10.1016/S0140-6736(00)04172-6 |url=}}</ref><ref name="pmid11571938">{{cite journal |vauthors=Findling JW, Raff H |title=Diagnosis and differential diagnosis of Cushing's syndrome |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=3 |pages=729–47 |year=2001 |pmid=11571938 |doi= |url=}}</ref><ref name="pmid9793762">{{cite journal |vauthors=Newell-Price J, Trainer P, Besser M, Grossman A |title=The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states |journal=Endocr. Rev. |volume=19 |issue=5 |pages=647–72 |year=1998 |pmid=9793762 |doi=10.1210/edrv.19.5.0346 |url=}}</ref><ref name="urlHow Is Metabolic Syndrome Diagnosed? - NHLBI, NIH">{{cite web |url=https://www.nhlbi.nih.gov/health/health-topics/topics/ms/diagnosis |title=How Is Metabolic Syndrome Diagnosed? - NHLBI, NIH |format= |work= |accessdate=}}</ref> | ||
<br> | <br> | ||
Line 36: | Line 38: | ||
*[[Kidney stone|Kidney stones]] | *[[Kidney stone|Kidney stones]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*24-hour urine cortisol | *24-hour urine [[cortisol]] | ||
*Midnight salivary cortisol | *Midnight salivary [[cortisol]] | ||
*[[Dexamethasone Oral|Low dose dexamethasone]] challenge test | *[[Dexamethasone Oral|Low dose dexamethasone]] challenge test | ||
*[[CRH]] stimulation | *[[CRH]] stimulation | ||
*[[Dexamethasone Oral|High dose dexamethasone]] test | *[[Dexamethasone Oral|High dose dexamethasone]] test | ||
*[[MRI|MRI brain]] | *[[MRI|MRI brain]] | ||
*CT/MRI adrenals | *CT/MRI [[adrenals]] | ||
|- | |- | ||
Line 58: | Line 60: | ||
*[[Oligomenorrhea]]/[[hypogonadism]] | *[[Oligomenorrhea]]/[[hypogonadism]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Urinary free cortisol | *Urinary free [[cortisol]] | ||
*Midnight salivary cortisol | *Midnight salivary [[cortisol]] | ||
*Low dose dexamethasone challenge test | *Low dose [[dexamethasone]] challenge test | ||
*[[Glucose tolerance test]] | *[[Glucose tolerance test]] | ||
*Loperamide test | *[[Loperamide]] test | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" |[[Metabolic syndrome X]] | | style="background:#DCDCDC;" align="center" |[[Metabolic syndrome X]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Familial/genetic | *Familial/[[genetic]] | ||
*Obesity | *[[Obesity]] | ||
*Insulin resistance | *[[Insulin]] resistance | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* [[Obesity]] | * [[Obesity]] | ||
Line 86: | Line 88: | ||
|} | |} | ||
=== | ===Differentials based on virilization and hirsutism=== | ||
Cushing's syndrome must be differentiated from diseases that cause [[virilization]] and [[hirsutism]] in female:<ref name="pmid24830586">{{cite journal |vauthors=Hohl A, Ronsoni MF, Oliveira Md |title=Hirsutism: diagnosis and treatment |journal=Arq Bras Endocrinol Metabol |volume=58 |issue=2 |pages=97–107 |year=2014 |pmid=24830586 |doi= |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref><ref name="ISBN:978-0323297387">{{cite book | last = Melmed | first = Shlomo | title = Williams textbook of endocrinology | publisher = Elsevier | location = Philadelphia, PA | year = 2016 | isbn = 978-0323297387 }}=</ref> | Cushing's syndrome must be differentiated from diseases that cause [[virilization]] and [[hirsutism]] in female:<ref name="pmid24830586">{{cite journal |vauthors=Hohl A, Ronsoni MF, Oliveira Md |title=Hirsutism: diagnosis and treatment |journal=Arq Bras Endocrinol Metabol |volume=58 |issue=2 |pages=97–107 |year=2014 |pmid=24830586 |doi= |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref><ref name="ISBN:978-0323297387">{{cite book | last = Melmed | first = Shlomo | title = Williams textbook of endocrinology | publisher = Elsevier | location = Philadelphia, PA | year = 2016 | isbn = 978-0323297387 }}=</ref> | ||
Line 183: | Line 185: | ||
|} | |} | ||
=== Differentials based on galactorrhea, amenorrhea and infertility === | |||
Cushing's syndrome should also be differentiated from other causes of [[hyperprolactinemia]] that may present as [[galactorrhea]], [[amenorrhea]], (in females) and [[infertility]] (in both males and females) including: | Cushing's syndrome should also be differentiated from other causes of [[hyperprolactinemia]] that may present as [[galactorrhea]], [[amenorrhea]], (in females) and [[infertility]] (in both males and females) including: | ||
*'''Physiological:''' | *'''Physiological:''' | ||
Line 410: | Line 412: | ||
|} | |} | ||
===Differentials based on irregular menstruation and hirsutism=== | |||
Cushing's syndrome must be differentiated from other causes of irregular menses and hirsutism. The differentials include: | |||
{| class="wikitable" | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Differentiating Features | |||
|- | |||
|[[Pregnancy]] | |||
| | |||
* Pregnancy should always be excluded in a patient with a history of [[amenorrhea]] | |||
* Features include [[amenorrhea]] or [[oligomenorrhea]], abnormal [[uterine]] bleeding, nausea/[[vomiting]], cravings, weight gain (although not in the early stages and not if vomiting), [[polyuria]], abdominal cramps and constipation, fatigue, dizziness/lightheadedness, and increased [[pigmentation]] (moles, nipples) | |||
* [[Uterine]] enlargement is detectable on [[abdominal]] examination at approximately 14 weeks of gestation | |||
* [[Ectopic]] pregnancy may cause [[oligomenorrhea]], [[amenorrhea]], or abnormal [[uterine]] bleeding with abdominal pain and sometimes subtle or absent physical symptoms and signs of pregnancy | |||
|- | |||
|[[Hypothalamic]] [[amenorrhea]] | |||
| | |||
* Diagnosis of exclusion | |||
* Seen in athletes, people on crash diets, patients with significant [[systemic]] illness, and those experiencing undue stress or anxiety | |||
* Predisposing features are as follows weight loss, particularly if features of anorexia nervosa are present or the BMI is <19 kg/m2 | |||
* Recent administration of depot [[Medroxyprogesterone (patient information)|medroxyprogesterone]], which may suppress [[ovarian]] activity for 6 months to a year | |||
* Use of [[dopamine]] [[agonists]] (eg, [[antidepressants]]) and major tranquilizers | |||
* [[Hyperthyroidism]] | |||
* In patients with weight loss related to [[anorexia nervosa]], fine hair growth (lanugo) may occur all over the body, but it differs from [[hirsutism]] in its fineness and wide distribution | |||
|- | |||
|[[Primary amenorrhea]] | |||
| | |||
* Causes include reproductive system abnormalities, [[chromosomal]] abnormalities, or delayed [[puberty]] | |||
* If [[secondary sexual characteristics]] are present, an anatomic abnormality (eg, imperforate [[hymen]], which is rare) should be considered | |||
* If [[secondary sexual characteristics]] are absent, a [[chromosomal]] abnormality (eg, Turner syndrome ) or delayed puberty should be considered | |||
|- | |||
|[[Cushing's syndrome|Cushing syndrome]] | |||
| | |||
* Cushing syndrome is due to excessive [[glucocorticoid]] secretion from the [[adrenal glands]], either primarily or secondary to stimulation from [[pituitary]] or [[ectopic]] hormones; can also be caused by [[exogenous]] [[steroid]] use | |||
* Features include [[hypertension]], weight gain (central distribution), [[acne]], and abdominal striae. Patients have low plasma sodium levels and elevated plasma [[Cortisol level|cortisol]] levels on [[Dexamethasone suppression test|dexamethasone suppression testing]] | |||
|- | |||
|[[Hyperprolactinemia]] | |||
| | |||
* Mild hyperprolactinemia may occur as part of PCOS-related hormonal dysfunction | |||
* Other causes include stress, lactation, and use of dopamine antagonists | |||
* A prolactinoma of the pituitary gland is an uncommon cause and should be suspected if prolactin levels are very high (>200 ng/mL) | |||
* Physical examination findings are usually normal | |||
* As in patients with PCOS, hyperprolactinemia may be associated with mild galactorrhea and oligomenorrhea or amenorrhea; however, galactorrhea also can occur with nipple stimulation and/or stress when prolactin levels are within normal ranges | |||
* A large prolactinoma may cause headaches and visual field disturbance due to pressure on the optic chiasm, classically a gradually increasing bi-temporal hemianopsia | |||
|- | |||
|Ovarian or adrenal tumor | |||
| | |||
* Benign ovarian tumors and ovarian cancer are rare causes of excessive androgen secretion; adrenocortical tumors also can increase the production of sex hormones | |||
* Abdominal swelling or mass, abdominal pain due to fluid leakage or torsion, dyspareunia, abdominal ascites, and features of metastatic disease may be present | |||
* Features of androgenization include hirsutism, weight gain, oligomenorrhea or amenorrhea, acne, clitoral hypertrophy, deepening of the voice, and high serum androgen (eg, testosterone, other androgens) levels | |||
* In patients with an androgen-secreting tumor, serum testosterone is not suppressed by dexamethasone | |||
|- | |||
|[[Congenital adrenal hyperplasia]] | |||
| | |||
* Congenital adrenal hyperplasia is a rare genetic condition resulting from 21-hydroxylase deficiency | |||
* The late-onset form presents at or around menarche Patients have features of androgenization and subfertility | |||
* Affects approximately 1% of hirsute patients More common in Ashkenazi Jews (19%), inhabitants of the former Yugoslavia (12%), and Italians (6%) | |||
* Associated with high levels of 17-hydroxyprogesterone | |||
* A short adrenocorticotropic hormone stimulation test with measurement of serum17-hydroxyprogesterone confirms the diagnosis Assays of a variety of androgenic hormones help define other rare adrenal enzyme deficiencies, which present similarly to 21-hydroxylase deficiency | |||
|- | |||
|Anabolic steroid abuse | |||
| | |||
* Anabolic steroids are synthetic hormones that imitate the actions of testosterone by increasing muscle bulk and strength | |||
* Should be considered if the patient is a serious sportswoman or bodybuilder | |||
* Features include virilization (including acne and hirsutism), often increased muscle bulk in male pattern, oligomenorrhea or amenorrhea, clitoromegaly, gastritis, hepatic enlargement, alopecia, and aggression | |||
* Altered liver function test results are seen | |||
|- | |||
|[[Hirsutism]] | |||
| | |||
* Hirsutism is excessive facial and body hair, usually coarse and in a male pattern of distribution | |||
* Approximately 10% of women report unwanted facial hair | |||
* There is often a family history and typically some Mediterranean or Middle Eastern ancestry | |||
* May also result from use of certain medications, both androgens, and others including danazol, glucocorticoids, cyclosporine, and phenytoin | |||
* Menstrual history is normal | |||
* When the cause is genetic, the excessive hair, especially on the face (upper lip), is present throughout adulthood, and there is no virilization | |||
* When secondary to medications, the excessive hair is of new onset, and other features of virilization, such as acne and deepened voice, may be present | |||
|} | |||
===Less common differentials=== | |||
Cushing's syndrome must be differentiated from other adrenal tumors such as [[adrenocortical adenoma]], adrenal [[metastasis]], and [[Pheochromocytoma|adrenal medullary tumors]]: | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center" | |||
|+ | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}} | |||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Clinical picture}} | |||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Imagings}} | |||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Laboratory tests}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Adrenocortica'''l carcinoma | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* Mass effect symptoms | |||
* Symptoms related to excess [[glucocorticoid]] | |||
* Symptoms related to excess [[mineralocorticoid]] | |||
* Symptoms related to excess [[androgen]] or [[estrogen]] secretion | |||
| | |||
* Irregular shape | |||
* Non-[[homogeneous]] density because of central areas of low attenuation due to [[tumor]] [[necrosis]] | |||
* [[Tumor]] [[calcification]] | |||
* Diameter usually >4 cm | |||
* Unilateral location | |||
* High unenhanced [[Computed tomography|CT]] attenuation values (>20 HU) | |||
* Non-[[homogeneous]] enhancement on [[Computed tomography|CT]] with [[intravenous]] [[Contrast medium|contrast]] | |||
* Delay in [[contrast medium]] washout (10 minutes after administration of [[contrast]], an absolute [[contrast medium]] washout of less than 50 percent) | |||
* Hypointensity compared with [[liver]] on T1 weighted [[Magnetic resonance imaging|MRI]] and high to intermediate signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]] | |||
* High standardized uptake value (SUV) on [[FDG-PET|FDG]]-[[PET scan|PET-CT]] study | |||
* Evidence of local [[invasion]] or [[Metastasis|metastases]] | |||
| | |||
* [[Androgen|Adrenal androgens]] ([[DHEAS|DHEAS)]] | |||
* [[Androstenedione]] | |||
* Bioavailable [[testosterone]] should be measured in every patient. | |||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | |||
* Serum [[estradiol]] in men and postmenopausal women | |||
* [[Cortisol level]] | |||
* Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal adenoma]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* Symptoms related to excess [[glucocorticoid]] | |||
* Symptoms related to excess [[mineralocorticoid]] | |||
| | |||
* Round, [[homogeneous]] with sharp margination | |||
* Unilateral with diameter less than 4 cm | |||
* Low unenhanced [[Computed tomography|CT]] attenuation values (<10 HU) | |||
* Rapid [[contrast medium]] washout after administration of contrast | |||
* An absolute [[contrast medium]] washout of more than 50 percent | |||
* [[Chemical shift]]: evidence of [[lipid]] on [[Magnetic resonance imaging|MRI]] | |||
* Isointensity with [[liver]] on both T1 and T2 weighted [[Magnetic resonance imaging|MRI]] sequences | |||
| | |||
* [[Cortisol level]] | |||
* Fasting [[serum]] [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime | |||
* [[Renin]] ([[Plasma renin activity|PRA]]) or plasma renin concentration (PRC): very low in patients with [[primary aldosteronism]], usually less than 1 ng/mL per hour for [[Plasma renin activity|PRA]] and usually undetectable for PRC<ref name="pmid26372319">{{cite journal| author=Manolopoulou J, Fischer E, Dietz A, Diederich S, Holmes D, Junnila R et al.| title=Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. | journal=J Hypertens | year= 2015 | volume= 33 | issue= 12 | pages= 2500-11 | pmid=26372319 | doi=10.1097/HJH.0000000000000727 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26372319 }}</ref> | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Cushing's syndrome]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]]) | |||
* Proximal [[muscle weakness]] | |||
* A [[round face]] often referred to as a "[[moon face]]" | |||
* Excess [[sweating]] | |||
* [[Headache]] | |||
| | |||
* Imaging may show [[mass]] if presents | |||
| | |||
* 24-hour [[urine]] [[cortisol]] | |||
* Midnight salivary [[cortisol]] | |||
* Low-dose [[dexamethasone]] suppression test; high [[cortisol]] level after the [[dexamethasone]] test is suggestive of [[hypercortisolism]]. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Pheochromocytoma]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* [[Palpitations]] especially in [[Epinephrine|epinephrine-]]<nowiki/>producing [[Tumor|tumors]]. | |||
* [[Anxiety]] often resembling that of a [[panic attack]] | |||
* [[Sweating]] | |||
* [[Headaches]] occur in 90 % of patients. | |||
* Paroxysmal attacks of [[hypertension]] but some patients have normal [[blood pressure]]. | |||
* It may be [[asymptomatic]] and discovered incidentally after [[Screening (medicine)|screening]] for [[MEN, type 2|MEN]] patients. | |||
| | |||
* Increased [[attenuation]] on non-enhanced [[Computed tomography|CT]] (>20 HU) | |||
* Increased [[mass]] [[vascularity]] | |||
* Delay in [[contrast medium]] washout (10 minutes after administration of [[contrast]], an absolute [[contrast medium]] washout of less than 50 percent) | |||
* High signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]] | |||
* [[Cystic]] and [[hemorrhagic]] changes | |||
* Variable size and may be [[bilateral]] | |||
| | |||
* [[Plasma]] fractionated [[Metanephrine|metanephrines]] | |||
* 24-hour [[urinary]] fractionated [[Metanephrine|metanephrines]] | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal metastasis]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* [[Symptoms]] and [[signs]] of primary [[malignancy]] especially [[lung cancer]] | |||
* General constitutional symptoms: | |||
**[[Fever]] | |||
**[[Fatigue]] | |||
**[[Weight loss]] | |||
| | |||
* Irregular shape and non-[[homogeneous]] nature | |||
* Tendency to be [[bilateral]] | |||
* High un-enhanced [[Computed tomography|CT]] [[attenuation]] values (>20 HU) and enhancement with [[Contrast medium|intravenous contrast]] on [[Computed tomography|CT]] | |||
* Delay in [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of less than 50 percent) | |||
* Isointensity or slightly less intense than the [[liver]] on T1 weighted [[Magnetic resonance imaging|MRI]] and high to intermediate signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]] (representing an increased water content) | |||
* Elevated standardized uptake value on [[FDG-PET|FDG]]-[[PET scan]] | |||
| | |||
|} | |||
==References== | ==References== |
Latest revision as of 19:25, 25 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Furqan M M. M.B.B.S[2]
Overview
Cushing's syndrome must be differentiated from other diseases that cause hypertension, obesity, and hyperandrogenism, such as Metabolic syndrome X and pseudo-Cushing's syndrome.
Differentiating Cushing's Syndrome From Other Diseases
Differentials based on hypertension, hyperandrogenism and obesity
The table below summarizes the findings that differentiate Cushing's disease from other conditions that may cause hypertension, hyperandrogenism, and obesity. Facial plethora, skin changes, osteoporosis, nephrolithiasis and neuropsychiatric conditions should raise the concern for Cushing's syndrome.[1][2][3][4]
Differentials based on virilization and hirsutismCushing's syndrome must be differentiated from diseases that cause virilization and hirsutism in female:[5][6][7]
Differentials based on galactorrhea, amenorrhea and infertilityCushing's syndrome should also be differentiated from other causes of hyperprolactinemia that may present as galactorrhea, amenorrhea, (in females) and infertility (in both males and females) including:
Differentials based on irregular menstruation and hirsutismCushing's syndrome must be differentiated from other causes of irregular menses and hirsutism. The differentials include:
Less common differentialsCushing's syndrome must be differentiated from other adrenal tumors such as adrenocortical adenoma, adrenal metastasis, and adrenal medullary tumors:
References
|